Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Medicare Bill Expands Competitive Bidding To DME Infusion Products

This article was originally published in The Gray Sheet

Executive Summary

Device industry concerns that an expanded Medicare competitive bidding program would eventually include new, high-end technologies may be alleviated by language in the "Medicare Prescription Drug & Modernization Act" of 2003, which specifically excludes Class III devices

You may also be interested in...



MedPAC Recommends Methods To Ease Transition To Competitive Bidding

Inclusion of a mandatory trial period in a competitive bidding program that allows Medicare beneficiaries to switch to a non-winning supplier if dissatisfied with the program's quality may be a way to gain beneficiary support for competitive bidding, according to MedPAC's 1June report

MedPAC Recommends Methods To Ease Transition To Competitive Bidding

Inclusion of a mandatory trial period in a competitive bidding program that allows Medicare beneficiaries to switch to a non-winning supplier if dissatisfied with the program's quality may be a way to gain beneficiary support for competitive bidding, according to MedPAC's 1June report

Glucose Monitor Manufacturers Wary As DME Competitive Bidding Looms

Blood glucose monitors and test strips are product areas that may fall under a competitive bidding model in upcoming Medicare reform legislation, according to device stakeholders

Related Content

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel